Entity family

Browse drugs

Named medicines, compounds, vaccines, and pharmacological agents. Examples include metformin, semaglutide, antibiotics.

4articles mentioning drugs

8drug mentions

1distinct drugs extracted

0%of mentions human-reviewed

Active filtersEntity: FLT3L ×

FLT3L

This drug is selected. Its supporting articles are shown below.

Articles mentioning FLT3L

4 articles · page 1 of 1

846 Flt3 ligand and CD40 agonist immunotherapy activates mature dendritic cells enriched in regulatory features with opposing IL-12 and CCL22 programs in breast cancer

jitc · abstract · 2025-11-04 · 3 matching annotations

86.7%

Doxil Flt3L triple-negative breast cancers triple-negative breast tumors

…rted after tumors reached 50 mm 3. Triplet therapy consisted of Doxil IV on day 1, Flt3L IP on days 1–5, and CD40a IP on days 11, 14,…

FLT3L-secreting cDC1 in situ vaccination enhances antitumor immunity and synergizes with PD-1 blockade in murine non-small cell lung cancer

jitc · abstract · 2026-06-25 · 2 matching annotations

90.8%

FLT3L FLT3L-cDC1 ISV FLT3L-cDC1 Non-small cell lung cancer NSCLC TCGA

… cDC1s engineered to secrete FMS-like tyrosine kinase 3 ligand (FLT3L) would enhance cDC1 function within the TME, promote antitumor …

628 CD40 agonist-based triplet therapy engages intra-tumoral T cells to drive tumor control independent of lymph node trafficking in triple negative breast cancers

jitc · abstract · 2025-11-04 · 2 matching annotations

87.6%

FTY720 Flt3L Doxil D1 TNBC NCT05029999 Triplet therapy anthracycline chemotherapy

…ansion of T cells. Notably, blockade of lymphocyte egress using FTY720 did not compromise therapeutic efficacy, suggesting that pre-ex…

Biomineralized engineered Lactococcus lactis-based in situ vaccination enhances antitumor immunity via sequential activation of chemo-immunotherapy

jitc · abstract · 2025-08-17 · 1 matching annotations

78.7%

vincristine cisplatin OX40L Flt3L Lactococcus lactis immunotherapy chemo-immunotherapy TME radiotherapy chemotherapy

… (Mg-metal-organic frameworks (MOFs)) loaded with cisplatin and vincristine (D&V@FOLactis) to achieve sequential activation of in situ anti…